
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.880 | 0.950 | 0.070 |
Stocks | 99.080 | 99.080 | 0.000 |
Bonds | 0.040 | 0.040 | 0.000 |
Convertible | 0.010 | 0.010 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 19.917 | 17.819 |
Price to Book | 3.172 | 3.653 |
Price to Sales | 5.844 | 5.347 |
Price to Cash Flow | 13.341 | 13.558 |
Dividend Yield | 0.299 | 0.514 |
5 Years Earnings Growth | 41.577 | 19.484 |
Number of long holdings: 49
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Argen-X | NL0010832176 | 8.14 | 619.20 | +0.55% | |
Scholar Rock | US80706P1030 | 5.67 | 37.70 | -3.70% | |
Arcutis | US03969K1088 | 4.75 | 13.02 | -2.98% | |
Zealand Pharma | DK0060257814 | 4.69 | 714.00 | -5.31% | |
Rhythm Pharma | US76243J1051 | 4.40 | 56.07 | -2.89% | |
Amgen | US0311621009 | 3.76 | 303.01 | +1.71% | |
Alnylam | US02043Q1076 | 3.70 | 250.59 | -0.16% | |
Vertex | US92532F1003 | 3.70 | 484.24 | +0.81% | |
Xenon Pharmaceuticals | CA98420N1050 | 3.60 | 39.73 | +0.89% | |
AstraZeneca | GB0009895292 | 3.44 | 11,708.0 | +1.02% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Global Technology Fund I E | 7.21B | 4.38 | 12.97 | 19.11 | ||
Global Technology Fund RE | 7.21B | 4.33 | 12.41 | 18.59 | ||
Global Technology FunD E | 7.21B | 30.70 | 6.50 | 17.81 | ||
IE00BZ4D7085 | 7.21B | 29.02 | 4.17 | - | ||
IE00BTN23623 | 7.21B | 3.98 | 9.29 | 16.01 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review